Taken together, these studies show that PRR antagonism is a new therapeutic approach that could be used to study physiological and pathophysiological roles of the PRR and as a new pharmacological approach for the treatment of cardio-renal and metabolic diseases. This evidence concerns the gene ATP6AP2 and metabolic disease.